ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
110.39
+9.49 (9.41%)
At close: Nov 14, 2025, 4:00 PM EST
110.37
-0.02 (-0.01%)
After-hours: Nov 14, 2025, 7:03 PM EST
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 69 employees as of December 31, 2024. The number of employees increased by 8 or 13.11% compared to the previous year.
Employees
69
Change (1Y)
8
Growth (1Y)
13.11%
Revenue / Employee
$102,513
Profits / Employee
-$3,325,555
Market Cap
8.27B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69 | 8 | 13.11% |
| Dec 31, 2023 | 61 | 37 | 154.17% |
| Dec 31, 2022 | 24 | 0 | - |
| Dec 31, 2021 | 24 | -3 | -11.11% |
| Dec 31, 2020 | 27 | 1 | 3.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABVX News
- 6 days ago - Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026 - Seeking Alpha
- 4 weeks ago - Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster - Seeking Alpha
- 5 weeks ago - ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript - Seeking Alpha
- 5 weeks ago - Why Is Abivax Stock Trading Higher On Monday? - Benzinga
- 5 weeks ago - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewsWire
- 6 weeks ago - Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 7 weeks ago - Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting - GlobeNewsWire
- 2 months ago - Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - GlobeNewsWire